Peter joined NDA in 2015. He is a leading expert in HTA, Market Access and Real-World Evidence and was instrumental in shaping the HTA conception for the German health care system and strategic reimbursement matters. Helping clients to navigate the drug development process and ultimately gain approval from regulators and payers alike.
Peter is also a Professor of Health Technology Assessment and Director of the Interdisciplinary Centre for Health Technology Assessment and Public Health, Friedrich-Alexander University of Erlangen-Nürnberg, Germany.
Key Areas Of Expertise
- Health Technology Assessment (HTA)
- Market Access
- Health Services Research
- Real-World Evidence
Before Joining The NDA Advisory Board
Peter was the Head of Department ‘Health Economics and Outcomes Research’ in the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne, the main scientific advisory body to the Federal Government and the Federal Joint Committee (GBA) representing the German Statutory Health Insurance System. Prof. Kolominsky-Rabas is one of a few experts in this field and is advising national health institutions in Germany as well as several government agencies in the EU.
M.D.; Ph.D; M.B.A.
Rücker V, Heuschmann PU, O'Flaherty M, Weingärtner M, Hess M, Sedlak C, Schwab S, Kolominsky-Rabas PL. Twenty-Year Time Trends in Long-Term Case-Fatality and Recurrence Rates After Ischemic Stroke Stratified by Etiology. Stroke. 2020 Sep;51(9):2778-2785. doi: 10.1161/STROKEAHA.120.029972. Epub 2020 Aug 19. PMID: 32811383.
Professor Peter Kolominsky-Rabas